Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost

Purpose: To compare the safety and efficacy of bimatoprost and latanoprost in patients with primary open-angle glaucoma or ocular hypertension. Method s: This was a 30-day, multicenter, double-masked, randomized, clinical tria l. Patients (n - 64) diagnosed with primary open-angle glaucoma or ocular h ypertension were randomly assigned to receive bimatoprost 0.03%, latanopros t 0.005%, or vehicle topically in both eyes once daily, in the evening, for 29days. The primary endpoint was the reduction in IOP from baseline on day 14 and day 29. Secondary outcome measures included eye examinations and sa fety parameters. Results: Bimatoprost and latanoprost significantly lowered IOP from baseline (p < .001). Bimatoprost lowered IOP more than latanopros t at every timepoint measured (bimatoprost: 25-34% reduction, 5.9-8.9 mm Hg ; latanoprost: 20-31% reduction, 4.4-7.9 mm Hg), although the between-group differences did not reach statistical significance. Over the 12-hour cours e of IOP measurements on day 29, bimatoprost provided better diurnal IOP co ntrol than latanoprost (p = .0378, area under the curve of diurnal IOP redu ctions, 1-way ANOVA with pairwise t-test). Both treatment regimens were saf e and well tolerated, with no significant between-group differences in repo rts of specific adverse events. The most common side effect was conjunctiva l hyperemia, which was similarly apparent in the bimatoprost 0.03% provided better diurnal IOP control than latanoprost and was safe and well tolerate d in patients with ocular hypertension and glaucoma. (C) 2001 by Elsevier S cience Inc. All rights reserved.